The Supreme Court on Thursday preserved access to the abortion pill mifepristone, rejecting a federal appeals court ruling that would have forced women to visit a doctor in person and halted mail delivery of the drug while a legal challenge from Louisiana works its way through the courts.
The justices granted emergency requests from drugmakers Danco Laboratories and GenBioPro, the companies that manufacture mifepristone, as the Associated Press reported. The order means women can continue obtaining the pill at pharmacies or through the mail without an in-person doctor visit, the same terms that have governed access for years.
Only Justices Samuel Alito and Clarence Thomas dissented. That lopsided margin is worth noting: the Court's conservative majority chose, at least for now, to leave the FDA's prescribing framework intact rather than let sweeping restrictions take hold mid-litigation.
Justice Alito did not go quietly. In a written dissent, he called the majority's reasoning thin. Breitbart reported that Alito wrote:
"The Court's unreasoned order granting stays in this case is remarkable."
Justice Thomas went further. He wrote that the two pharmaceutical companies are not entitled to the Court's intervention to spare them "lost profits from their criminal enterprise," the New York Post reported. That language, "criminal enterprise", signals how seriously Thomas views the underlying dispute over the FDA's authority to loosen prescribing rules for a drug used to end pregnancies.
For pro-life advocates who hoped this Court would move aggressively after overturning Roe v. Wade four years ago, the order lands as another frustration. The same two justices, Alito and Thomas, were the lone dissenters when the Court previously blocked a 5th Circuit ruling on mifepristone from taking effect in the earlier round of this fight.
The case at the center of Thursday's order originated in Louisiana, which filed suit to roll back the FDA's rules governing how mifepristone can be prescribed. Louisiana's argument is straightforward: the state has an abortion ban, and federal rules that allow the drug to flow through the mail and via telehealth undermine that ban. The state also questions the safety of the drug itself.
A three-judge panel of the 5th U.S. Circuit Court of Appeals sided with Louisiana, ruling that mail access and telehealth prescribing should be suspended while the case plays out. That ruling would have forced women to see a doctor in person before obtaining mifepristone, reversing a change the FDA made roughly five years ago when it dropped the in-person visit requirement.
The Supreme Court's order effectively freezes the status quo. Access to mifepristone is likely to remain uninterrupted at least into next year as the litigation continues, including a potential appeal back to the high court.
This is not the first time the justices have dealt with mifepristone. A similar dispute reached the Court about three years ago. In 2024, the high court unanimously dismissed a lawsuit brought by physicians who oppose abortion, ruling those doctors lacked standing to sue. Louisiana's challenge, filed by the state itself, was designed to clear that procedural hurdle.
The FDA first approved mifepristone for use in abortion in 2000. In the quarter-century since, the drug has become the dominant method of ending pregnancies in America. Medication abortions accounted for nearly two-thirds of all abortions in the United States in 2023, the last year for which statistics are available.
That market reality explains why the pharmaceutical industry weighed in alongside mainstream medical groups and Democratic members of Congress, all cautioning the Court against limiting access. Pharmaceutical companies warned that a ruling for abortion opponents would upend the broader drug-approval process, an argument that likely carried weight with justices wary of disrupting regulatory frameworks beyond the abortion context.
The debate over mifepristone's safety has churned for more than 25 years, with neither side yielding. Pro-life groups see the FDA's loosened prescribing rules as a backdoor around state abortion bans. Supporters of access argue the drug's safety record is well-established and that restricting it would harm women in states where abortion remains legal.
The Court has been active on several fronts this term, issuing a series of orders that have drawn sharp reactions from across the political spectrum. Thursday's mifepristone order adds to a pattern in which the justices have shown willingness to act as a check on lower courts, sometimes in ways that frustrate the conservative base.
One of the most telling details in Thursday's order is what the Trump administration did not do. Despite federal regulations being directly at issue, the administration declined to file a written brief recommending what the Court should do.
That silence speaks volumes. Anti-abortion groups have grown increasingly frustrated with the administration's posture on mifepristone. Susan B. Anthony Pro-Life America called on President Trump to fire FDA Commissioner Marty Makary over the slow pace of the agency's mifepristone review. Makary resigned earlier this week after months of criticism from Trump's political allies, including abortion opponents.
Trump has relied heavily on the political support of anti-abortion groups, and their patience appears to be wearing thin. The administration's decision to sit out the Supreme Court briefing, neither defending the FDA's current rules nor siding with Louisiana, left both sides without a clear signal of where the executive branch stands.
That kind of strategic ambiguity may serve short-term political interests. But it also means the Court acted without the benefit of the federal government's legal position on its own regulations, an unusual posture for a case of this magnitude.
The order does not resolve the underlying legal questions. Louisiana's lawsuit will continue in the lower courts, and the case could return to the Supreme Court on the merits. For now, the justices have simply preserved the pre-existing rules while that process unfolds.
The Just the News report on the ruling noted that the order allows women to continue accessing mifepristone through telehealth visits and mail delivery nationwide, a framework that has been in place for years and that the 5th Circuit sought to dismantle.
For pro-life advocates, the path forward remains the lower courts. If Louisiana prevails on the merits, the case will return to the Supreme Court with a full record and full briefing, a very different posture than an emergency stay request. The legal fight over mifepristone is far from over.
The Court's recent term has produced a string of decisions that defied easy ideological sorting, from redistricting rulings that reshaped the congressional map to regulatory disputes that crossed traditional partisan lines. Thursday's mifepristone order fits that pattern. The conservative majority did not side with the pro-life movement on the emergency request, but neither did it foreclose the underlying legal challenge.
Meanwhile, the political fallout will continue. Pro-life groups expected more from a Court that overturned Roe and from an administration that courted their votes. The administration's refusal to take a position, combined with Makary's departure from the FDA, leaves abortion opponents without a clear champion in either branch.
The broader landscape of Supreme Court intervention in politically charged cases continues to shift in ways that both parties find uncomfortable at different turns. That is, in its own way, a sign the institution is functioning, even when the results frustrate the people who expected the most from it.
When the government you elected won't even file a brief in your case, and the Court you helped build won't grant you emergency relief, the message is plain enough: winning elections and confirming justices is not the same as winning the argument.